.Pharmacolibrary.Drugs.ATC.C.C09CA07

Information

Telmisartan is an angiotensin II receptor antagonist (ARB) used clinically for the treatment of hypertension. It is also indicated for the reduction of cardiovascular risk in patients with a high risk of cardiovascular events. Telmisartan is approved and widely used today.

Pharmacokinetics

Pharmacokinetic data obtained from studies in healthy adult subjects, after a single oral dose.

References

1. Huang, L, et al., & Pei, Q (2019). Effects of UGT1A1 Polymorphism, Gender and Triglyceride on the Pharmacokinetics of Telmisartan in Chinese Patients with Hypertension: A Population Pharmacokinetic Analysis. European journal of drug metabolism and pharmacokinetics 44(6) 797–806. DOI:10.1007/s13318-019-00567-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31254178

2. Guo, X, et al., & Li, YJ (2009). No effect of MDR1 C3435T polymorphism on oral pharmacokinetics of telmisartan in 19 healthy Chinese male subjects. Clinical chemistry and laboratory medicine 47(1) 38–43. DOI:10.1515/CCLM.2009.019 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19072027

3. Miura, M, et al., & Suzuki, T (2009). Telmisartan pharmacokinetics in Japanese renal transplant recipients. Clinica chimica acta; international journal of clinical chemistry 399(1-2) 83–87. DOI:10.1016/j.cca.2008.09.020 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18838068

Revisions

• 06/2025 initial generated model